| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Uremia | D014511 | 33 associated lipids |
| Colitis, Ulcerative | D003093 | 24 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Kidney Failure, Chronic | D007676 | 51 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Graft Occlusion, Vascular | D006083 | 11 associated lipids |
| Hypercalcemia | D006934 | 13 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Kawazoe H et al. | Change of the blood concentration of tacrolimus after the switch from fluconazole to voriconazole in patients receiving allogeneic hematopoietic stem cell transplantation. | 2006 | Biol. Pharm. Bull. | pmid:17142996 |
| Sakamoto Y et al. | Correlation between neurotoxic events and intracerebral concentration of tacrolimus in rats. | 2000 | Biol. Pharm. Bull. | pmid:10963314 |
| Miura M et al. | Inter-laboratory Variability of Current Immunoassay Methods for Tacrolimus among Japanese Hospitals. | 2016 | Biol. Pharm. Bull. | pmid:27263473 |
| DiMartini AF et al. | Prospective study of FK506 side effects: anxiety or akathisia? | 1996 | Biol. Psychiatry | pmid:8874843 |
| Baldari CT et al. | NF-AT-luciferase reporter T cell lines as tools to screen immunosuppressive drugs. | 1998 | Biologicals | pmid:9637743 |
| Wang M et al. | Enteric polymer based on pH-responsive aliphatic polycarbonate functionalized with vitamin E to facilitate oral delivery of tacrolimus. | 2015 | Biomacromolecules | pmid:25714622 |
| Fathy M et al. | Impact of CYP3A5 and MDR-1 gene polymorphisms on the dose and level of tacrolimus among living-donor liver transplanted patients: single center experience. | 2016 | Biomarkers | pmid:26856709 |
| Wang JL et al. | Delivery of tacrolimus with cationic lipid-assisted nanoparticles for ulcerative colitis therapy. | 2018 | Biomater Sci | pmid:29850666 |
| Pham TT et al. | Tissue adhesive FK506-loaded polymeric nanoparticles for multi-layered nano-shielding of pancreatic islets to enhance xenograft survival in a diabetic mouse model. | 2018 | Biomaterials | pmid:29128846 |
| Jeong JH et al. | Surface camouflage of pancreatic islets using 6-arm-PEG-catechol in combined therapy with tacrolimus and anti-CD154 monoclonal antibody for xenotransplantation. | 2011 | Biomaterials | pmid:21831422 |
| Im BH et al. | The effects of 8-arm-PEG-catechol/heparin shielding system and immunosuppressive drug, FK506 on the survival of intraportally allotransplanted islets. | 2013 | Biomaterials | pmid:23261215 |
| Zadrazil J et al. | Protocol biopsy and subclinical rejection in patients after kidney transplantation treated by tacrolimus (Prograf). | 2003 | Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub | pmid:15037903 |
| Krejci K et al. | Calcineurin inhibitor-induced renal allograft nephrotoxicity. | 2010 | Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub | pmid:21293540 |
| Zadrazil J et al. | Improvement of cardiovascular risk factors and cosmetic side effects in kidney transplant recipients after conversion to tacrolimus. | 2009 | Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub | pmid:19365530 |
| Zadrazil J et al. | In vivo oxidized low-density lipoprotein (ox-LDL) aopp and tas after kidney transplantation: a prospective, randomized one year study comparing cyclosporine A and tacrolimus based regiments. | 2012 | Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub | pmid:22580856 |
| Krejci K et al. | Clinical experience of conversion from cyclosporine to tacrolimus prolonged-release in stabilized kidney transplant patients. | 2016 | Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub | pmid:27174195 |
| Torres IB et al. | The Interplay between inflammation and fibrosis in kidney transplantation. | 2014 | Biomed Res Int | pmid:24991565 |
| Zhang J et al. | Helminth protein vaccine induced follicular T helper cell for enhancement of humoral immunity against Schistosoma japonicum. | 2013 | Biomed Res Int | pmid:24308005 |
| Thorat A et al. | Effects of converting tacrolimus formulation from twice-daily to once-daily in liver transplantation recipients. | 2014 | Biomed Res Int | pmid:25121091 |
| Ko SF et al. | Therapeutic potential of tacrolimus on acute myocardial infarction in minipigs: analysis with serial cardiac magnetic resonance and changes at histological and protein levels. | 2014 | Biomed Res Int | pmid:25114905 |
| Al-Harbi NO et al. | Olmesartan attenuates tacrolimus-induced biochemical and ultrastructural changes in rat kidney tissue. | 2014 | Biomed Res Int | pmid:24987695 |
| Krzyżowska K et al. | Which Kidney Transplant Recipients Can Benefit from the Initial Tacrolimus Dose Reduction? | 2018 | Biomed Res Int | pmid:29651435 |
| Jovanović M and Golušin Z | Nonsteroidal Topical Immunomodulators in Allergology and Dermatology. | 2016 | Biomed Res Int | pmid:27144167 |
| Mochizuki N et al. | Liquid chromatographic method for the determination of sirolimus in blood using electrochemical detection. | 2009 | Biomed. Chromatogr. | pmid:18814192 |
| Li Q et al. | Development and validation of a sensitive LC-MS/MS method for determination of tacrolimus on dried blood spots. | 2013 | Biomed. Chromatogr. | pmid:22893355 |
| Burhenne H et al. | Quantitative analysis of the antifungal drug anidulafungin by LC-online SPE-MS/MS in human plasma. | 2012 | Biomed. Chromatogr. | pmid:22020627 |
| Ma L et al. | Comparison of release and penetration of tacrolimus ointment reference and trial formulation after dermal application to pigs by liquid chromatography-electrospray ionization tandem mass spectrometry. | 2013 | Biomed. Chromatogr. | pmid:23657920 |
| Qin XL et al. | Study of the effect of Wuzhi tablet (Schisandra sphenanthera extract) on tacrolimus tissue distribution in rat by liquid chromatography tandem mass spectrometry method. | 2010 | Biomed. Chromatogr. | pmid:19693766 |
| Xia T et al. | Targeted metabolomic analysis of 33 amino acids and biogenic amines in human urine by ion-pairing HPLC-MS/MS: Biomarkers for tacrolimus nephrotoxicity after renal transplantation. | 2018 | Biomed. Chromatogr. | pmid:29369388 |
| Gagliano N et al. | Differential effect of Cyclosporin A and FK506 on SPARC mRNA expression by human gingival fibroblasts. | 2005 | Biomed. Pharmacother. | pmid:15890490 |
| Sir G et al. | Antagonistic Effect of Oxytocin and Tacrolimus Combination on Adipose Tissue - Derived Mesenchymal Stem Cells: Antagonistic effect of oxytocin and tacrolimus. | 2018 | Biomed. Pharmacother. | pmid:29136956 |
| Ma X et al. | Inhibition effect of tacrolimus and platelet-derived growth factor-BB on restenosis after vascular intimal injury. | 2017 | Biomed. Pharmacother. | pmid:28633129 |
| Ori Y et al. | Effect of immunosuppressive drugs on spontaneous DNA repair in human peripheral blood mononuclear cells. | 2012 | Biomed. Pharmacother. | pmid:22795807 |
| Lee C et al. | Treatment of bleomycin-induced pulmonary fibrosis by inhaled tacrolimus-loaded chitosan-coated poly(lactic-co-glycolic acid) nanoparticles. | 2016 | Biomed. Pharmacother. | pmid:26898446 |
| Fan B et al. | Prograf produces more benefits for CYP3A5 low expression patients in early stage after kidney transplantation. | 2017 | Biomed. Pharmacother. | pmid:28157649 |
| von Suesskind-Schwendi M et al. | Pharmacokinetics of a self-microemulsifying drug delivery system of tacrolimus. | 2013 | Biomed. Pharmacother. | pmid:23669280 |
| Zhang X et al. | Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic considerations. | 2018 | Biomed. Pharmacother. | pmid:29550633 |
| Kalam MA and Alshamsan A | Poly (d, l-lactide-co-glycolide) nanoparticles for sustained release of tacrolimus in rabbit eyes. | 2017 | Biomed. Pharmacother. | pmid:28772219 |
| Kanda J et al. | Effects of the calcineurin inhibitors cyclosporine and tacrolimus on bone metabolism in rats. | 2018 | Biomed. Res. | pmid:29899188 |
| Alag R et al. | NMR assignments of the FK506-binding domain of FK506-binding protein 35 from Plasmodium vivax. | 2009 | Biomol NMR Assign | pmid:19774494 |
| Moda TL et al. | Hologram QSAR model for the prediction of human oral bioavailability. | 2007 | Bioorg. Med. Chem. | pmid:17870541 |
| Yli-Kauhaluoma J and Janda KD | Twisted alpha-keto amides as transition-state analogues for acyl-transfer reactions: synthesis of the immunoconjugates. | 1994 | Bioorg. Med. Chem. | pmid:7528089 |
| Piggott AM et al. | Rapid isolation of novel FK506 binding proteins from multiple organisms using gDNA and cDNA T7 phage display. | 2009 | Bioorg. Med. Chem. | pmid:19740670 |
| Mori T et al. | An easy preparation of 'monolithic type' hydrophilic solid phase: capability for affinity resin to isolate target proteins. | 2006 | Bioorg. Med. Chem. | pmid:16682207 |
| Adalsteinsson H and Bruice TC | Generation and evaluation of putative neuroregenerative drugs. Part 1: virtual point mutations to the polyketide rapamycin. | 2000 | Bioorg. Med. Chem. | pmid:10732978 |
| Marinec PS et al. | Synthesis of orthogonally reactive FK506 derivatives via olefin cross metathesis. | 2009 | Bioorg. Med. Chem. | pmid:19643614 |
| Furuya M et al. | Reduction of nonspecific binding proteins to self-assembled monolayer on gold surface. | 2006 | Bioorg. Med. Chem. | pmid:16314102 |
| Ivery MT and Weiler L | Modeling the interaction between FK506 and FKBP12: a mechanism for formation of the calcineurin inhibitory complex. | 1997 | Bioorg. Med. Chem. | pmid:9061187 |
| Ivery MT | A proposed molecular model for the interaction of calcineurin with the cyclosporin A-cyclophilin A complex. | 1999 | Bioorg. Med. Chem. | pmid:10465413 |
| Xie C et al. | Vialinin B, a novel potent inhibitor of TNF-alpha production, isolated from an edible mushroom, Thelephora vialis. | 2006 | Bioorg. Med. Chem. Lett. | pmid:16901696 |
| Iwaoka E et al. | Improvement of monolithic solid material by utilization of spacer for identification of the target using affinity resins. | 2009 | Bioorg. Med. Chem. Lett. | pmid:19201607 |
| Mabuchi M et al. | Improvement of solid material for affinity resins by application of long PEG spacers to capture the whole target complex of FK506. | 2015 | Bioorg. Med. Chem. Lett. | pmid:26025877 |
| Mabuchi M et al. | Selective elution of target protein from affinity resins by a simple reductant with a thiol group. | 2010 | Bioorg. Med. Chem. Lett. | pmid:21067925 |
| Takahashi Y et al. | Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. | 2006 | Bioorg. Med. Chem. Lett. | pmid:16682195 |
| Goulet MT et al. | C32-O-phenalkyl ether derivatives of the immunosuppressant ascomycin: a tether length study. | 1999 | Bioorg. Med. Chem. Lett. | pmid:10450986 |
| Armstrong HM et al. | Potent immunosuppressive C32-O-arylethyl ether derivatives of ascomycin with reduced toxicity. | 1999 | Bioorg. Med. Chem. Lett. | pmid:10450987 |
| Okada K et al. | Vialinin A is a ubiquitin-specific peptidase inhibitor. | 2013 | Bioorg. Med. Chem. Lett. | pmid:23791076 |
| Nambu M et al. | A calcineurin antifungal strategy with analogs of FK506. | 2017 | Bioorg. Med. Chem. Lett. | pmid:28412204 |
| Hersperger R et al. | Preparation and immunosuppressive activity of 32-(O)-acylated and 32-(O)-thioacylated analogues of ascomycin. | 1999 | Bioorg. Med. Chem. Lett. | pmid:10021934 |
| Dubowchik GM et al. | Fluoresceinated FKBP12 ligands for a high-throughput fluorescence polarization assay. | 2000 | Bioorg. Med. Chem. Lett. | pmid:10741553 |
| Yang W et al. | Regulation of gene expression by synthetic dimerizers with novel specificity. | 2003 | Bioorg. Med. Chem. Lett. | pmid:12951089 |
| Kawai M et al. | Studies on an immunosuppressive macrolactam, ascomycin: synthesis of a C-33 hydroxyl derivative. | 1998 | Bioorg. Med. Chem. Lett. | pmid:9871515 |
| Nishiya Y et al. | A new efficient method of generating photoaffinity beads for drug target identification. | 2017 | Bioorg. Med. Chem. Lett. | pmid:28108248 |
| Schultz LW and Clardy J | Chemical inducers of dimerization: the atomic structure of FKBP12-FK1012A-FKBP12. | 1998 | Bioorg. Med. Chem. Lett. | pmid:9871618 |
| Goulet MT et al. | C32-O-imidazol-2-yl-methyl ether derivatives of the immunosuppressant ascomycin with improved therapeutic potential. | 1998 | Bioorg. Med. Chem. Lett. | pmid:9873523 |
| Takahashi T et al. | Development of chemically stable solid phases for the target isolation with reduced nonspecific binding proteins. | 2006 | Bioorg. Med. Chem. Lett. | pmid:16290149 |
| Zhao L et al. | Modeling and synthesis of non-cyclic derivatives of GPI-1046 as potential FKBP ligands with neurotrophic properties. | 2006 | Bioorg. Med. Chem. Lett. | pmid:16753298 |
| Rabinowitz M et al. | Solid-phase/solution-phase combinatorial synthesis of neuroimmunophilin ligands. | 2000 | Bioorg. Med. Chem. Lett. | pmid:10843203 |
| Ye YQ et al. | Design and synthesis of a vialinin A analog with a potent inhibitory activity of TNF-α production and its transformation into a couple of bioprobes. | 2012 | Bioorg. Med. Chem. Lett. | pmid:22410084 |
| Wang YH et al. | Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism. | 2005 | Bioorg. Med. Chem. Lett. | pmid:15990295 |
| Jogiraju VK et al. | Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations. | 2017 | Biopharm Drug Dispos | pmid:28474821 |
| Watanabe N et al. | The possible clinical impact of risperidone on P-glycoprotein-mediated transport of tacrolimus: A case report and in vitro study. | 2018 | Biopharm Drug Dispos | pmid:29055041 |
| Miao LY et al. | Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. | 2008 | Biopharm Drug Dispos | pmid:17941052 |
| Frassetto L et al. | Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. | 2013 | Biopharm Drug Dispos | pmid:24030928 |
| Pietruck F et al. | Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients. | 2005 | Biopharm Drug Dispos | pmid:15768377 |
| Ohtani H et al. | Bottom-up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power. | 2011 | Biopharm Drug Dispos | pmid:22028295 |
| Miura M et al. | Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. | 2007 | Biopharm Drug Dispos | pmid:17377957 |
| Barter ZE et al. | Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations. | 2010 | Biopharm Drug Dispos | pmid:21104927 |
| Takada K et al. | Distribution characteristics of immunosuppressants FK506 and cyclosporin A in the blood compartment. | 1993 | Biopharm Drug Dispos | pmid:7508273 |
| Yamada H et al. | Simvastatin-tacrolimus and simvastatin-cyclosporin interactions in rats. | 1998 | Biopharm Drug Dispos | pmid:9673778 |
| Oda K and Yamano K | Effect of telaprevir on the metabolism and hepatic uptake of tacrolimus (FK506). | 2014 | Biopharm Drug Dispos | pmid:25059890 |
| Takada K et al. | Distribution kinetics of FK-506, a novel immunosuppressant, after intravenous administration to rats in comparison with cyclosporin A. | 1992 | Biopharm Drug Dispos | pmid:1379839 |
| Oda K et al. | In vitro-in vivo extrapolations to evaluate the effect of concomitant drugs on tacrolimus (FK506) exposure. | 2015 | Biopharm Drug Dispos | pmid:25600613 |
| Oda K et al. | In vitro experimental system for evaluating inhibitory effect of investigational drugs on P-glycoprotein-mediated transcellular transport of tacrolimus (FK506). | 2014 | Biopharm Drug Dispos | pmid:24822242 |
| Anderson JS et al. | Statistical allosteric coupling to the active site indole ring flip equilibria in the FK506-binding domain. | 2014 | Biophys. Chem. | pmid:25016286 |
| Kovermann M and Balbach J | Dynamic control of the prolyl isomerase function of the dual-domain SlyD protein. | 2013 | Biophys. Chem. | pmid:23268194 |
| Sobie EA et al. | Termination of cardiac Ca(2+) sparks: an investigative mathematical model of calcium-induced calcium release. | 2002 | Biophys. J. | pmid:12080100 |
| Wang J et al. | Absolute binding free energy calculations using molecular dynamics simulations with restraining potentials. | 2006 | Biophys. J. | pmid:16844742 |
| Sun F et al. | Design and structure-based study of new potential FKBP12 inhibitors. | 2003 | Biophys. J. | pmid:14581219 |
| Silva ND and Prendergast FG | Tryptophan dynamics of the FK506 binding protein: time-resolved fluorescence and simulations. | 1996 | Biophys. J. | pmid:8785272 |
| Wagenknecht T et al. | Cryoelectron microscopy resolves FK506-binding protein sites on the skeletal muscle ryanodine receptor. | 1996 | Biophys. J. | pmid:8785329 |
| Lee MS and Olson MA | Calculation of absolute protein-ligand binding affinity using path and endpoint approaches. | 2006 | Biophys. J. | pmid:16284269 |
| Ma J et al. | Rectification of skeletal muscle ryanodine receptor mediated by FK506 binding protein. | 1995 | Biophys. J. | pmid:8599646 |
| Xu RX et al. | 1H, 13C, and 15N assignments and secondary structure of the FK506 binding protein when bound to ascomycin. | 1993 | Biopolymers | pmid:7682113 |
| Taylor P et al. | Conformational polymorphism in peptidic and nonpeptidic drug molecules. | 1996 | Biopolymers | pmid:9101762 |
| Moore JM | NMR techniques for characterization of ligand binding: utility for lead generation and optimization in drug discovery. | 1999 | Biopolymers | pmid:10516573 |
| Wang XJ and Etzkorn FA | Peptidyl-prolyl isomerase inhibitors. | 2006 | Biopolymers | pmid:16302169 |
| Sugawara Y et al. | Once-daily tacrolimus in living donor liver transplant recipients. | 2011 | Biosci Trends | pmid:21914950 |
| Hiraga K et al. | A novel screening for inhibitors of a pleiotropic drug resistant pump, Pdr5, in Saccharomyces cerevisiae. | 2001 | Biosci. Biotechnol. Biochem. | pmid:11515543 |
| Kume K et al. | Screening for a gene deletion mutant whose temperature sensitivity is suppressed by FK506 in budding yeast and its application for a positive screening for drugs inhibiting calcineurin. | 2015 | Biosci. Biotechnol. Biochem. | pmid:25614218 |